Solutions

Pivotal clinical trials cost an average of $48 million, yet 90% fail to meet their intended outcomes, with only 10% succeeding. The high failure rate is largely attributed to poor trial design, inefficient patient recruitment, and flawed endpoint selection.

Clinical trials remain the foundation of medical advancement, essential for bringing new drugs and medical devices to market. However, the traditional methodologies for trial design have remained unchanged for decades. In a landscape where diseases progress rapidly and resource constraints intensify, biopharmaceutical companies and Clinical Research Organisations (CROs) struggle to optimise trials effectively.

Market-leading +92% accuracy in predicting clinical trial completion

Our platform is trained using data from over
468,429 clinical trials and 1300+ variables

Each trial is simulated up to 100,000 times provides robust, reliable predictions, ensuring data-driven biostatistical validation for optimised trial designs

Drawing on over 30 years of real-world trial data, TrialKey employs advanced AI and Natural Language Processing (NLP) to optimise clinical trial design and improve resource allocation. Our platform offers comprehensive insights into competitor trials and similar studies across a range of drugs, medical devices, alternative therapies, and novel conditions, providing specific recommendations to enhance trial outcomes. 

With a detailed analysis, TrialKey not only identifies areas of risk but also offers actionable recommendations, ensuring your trial design is aligned for maximum success.

How Opyl’s TrialKey is Changing Clinical Trials

Opyl leverages AI-powered biostatistical validation and predictive analytics through TrialKey to enhance efficiency, reduce costs, and improve clinical trial success rates.

By analysing real-world trial data and using machine learning, TrialKey enables:

• Access to data from 468,429 clinical trials, 114,925 conditions, and 2.69 billion patients
• Prediction of trial success probabilities with 92%+ accuracy
• In-depth insights into over 1,300 trial variables
• Identification of the most optimal inclusion/exclusion criteria to reduce dropouts
• Improved site selection and patient recruitment strategies
• Simulation of clinical trials up to 100,000 times for validation
• Comparison against competitor trials and historical benchmarks
• Custom analytical reports detailing study design, endpoints, and risk factors
• Forecasting of drug approval inflection points
• A clinical trial simulator to test and refine trial protocols before execution

Driving Smarter, Faster, and More Cost-Effective Clinical Trials

TrialKey’s AI-driven approach empowers pharmaceutical companies, CROs, and investors by providing actionable intelligence and real-time trial simulations. By leveraging cutting-edge biostatistical validation, TrialKey significantly reduces trial costs while increasing success probabilities across all trial phases.

These insights allow stakeholders to:

• Optimise resource allocation to high-probability trials
• Enhance trial design with data-driven modifications
• Reduce costly amendments and accelerate market entry
• Improve decision-making with transparent, evidence-based predictions

With TrialKey, Opyl is transforming clinical research, making trials more predictable, cost-efficient, and effective.